A citation-based method for searching scientific literature

Ian J Neeland, Usman Salahuddin, Darren K McGuire. Expert Opin Drug Saf 2016
Times Cited: 8







List of co-cited articles
23 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
50

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
37


Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Hans J Woerle, Uli C Broedl. Diabetes Care 2013
282
37


Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.
R Grempler, L Thomas, M Eckhardt, F Himmelsbach, A Sauer, D E Sharp, R A Bakker, M Mark, T Klein, P Eickelmann. Diabetes Obes Metab 2012
396
25

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
Anthony H Barnett, Ambrish Mithal, Jenny Manassie, Russell Jones, Henning Rattunde, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
392
25

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.
Michael Roden, Jianping Weng, Jens Eilbracht, Bruno Delafont, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2013
328
25

Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
Ralph A DeFronzo, Andrew Lewin, Sanjay Patel, Dacheng Liu, Renee Kaste, Hans J Woerle, Uli C Broedl. Diabetes Care 2015
217
25

Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Uli C Broedl, Hans J Woerle. Diabetes Care 2014
272
25



Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.
Muhammad A Abdul-Ghani, Luke Norton, Ralph A Defronzo. Endocr Rev 2011
288
25


Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial.
Eirik Søfteland, Juris J Meier, Bente Vangen, Robert Toorawa, Mario Maldonado-Lutomirsky, Uli C Broedl. Diabetes Care 2017
75
25

Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Christoph Wanner, John M Lachin, Silvio E Inzucchi, David Fitchett, Michaela Mattheus, Jyothis George, Hans J Woerle, Uli C Broedl, Maximilian von Eynatten, Bernard Zinman. Circulation 2018
260
25

Efficacy and safety of empagliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.
R Devi, Ghanshyam Mali, Indrani Chakraborty, Mazhuvancherry Kesavan Unnikrishnan, Suhaj Abdulsalim. Postgrad Med 2017
17
25

Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.
A Liakos, T Karagiannis, E Athanasiadou, M Sarigianni, M Mainou, K Papatheodorou, E Bekiari, A Tsapas. Diabetes Obes Metab 2014
145
25

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
25

Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.
Ralph A DeFronzo, Luke Norton, Muhammad Abdul-Ghani. Nat Rev Nephrol 2017
270
25


Empagliflozin (Jardiance): A Novel SGLT2 Inhibitor for the Treatment of Type-2 Diabetes.
Uche Anadu Ndefo, Nicole O Anidiobi, Efrah Basheer, Angie T Eaton. P T 2015
24
25

Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials.
Katherine R Tuttle, Adeera Levin, Masaomi Nangaku, Takashi Kadowaki, Rajiv Agarwal, Sibylle J Hauske, Amelie Elsäßer, Ivana Ritter, Dominik Steubl, Christoph Wanner,[...]. Diabetes Care 2022
3
66




Identification of type 1 diabetes-associated DNA methylation variable positions that precede disease diagnosis.
Vardhman K Rakyan, Huriya Beyan, Thomas A Down, Mohammed I Hawa, Siarhei Maslau, Deeqo Aden, Antoine Daunay, Florence Busato, Charles A Mein, Burkhard Manfras,[...]. PLoS Genet 2011
219
12

Epigenetic mechanisms of endothelial dysfunction in type 2 diabetes.
Francesco Prattichizzo, Angelica Giuliani, Artan Ceka, Maria Rita Rippo, Anna Rita Bonfigli, Roberto Testa, Antonio Domenico Procopio, Fabiola Olivieri. Clin Epigenetics 2015
57
12

Targeting chromatin remodeling to prevent cardiovascular disease in diabetes.
Sarah Costantino, Francesco Paneni, Francesco Cosentino. Curr Pharm Biotechnol 2015
22
12


Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association.
Caroline S Fox, Sherita Hill Golden, Cheryl Anderson, George A Bray, Lora E Burke, Ian H de Boer, Prakash Deedwania, Robert H Eckel, Abby G Ershow, Judith Fradkin,[...]. Diabetes Care 2015
266
12

Fenofibrate suppresses cellular metabolic memory of high glucose in diabetic retinopathy via a sirtuin 1-dependent signalling pathway.
Shuzhi Zhao, Jun Li, Na Wang, Bingqing Zheng, Tao Li, Qing Gu, Xun Xu, Zhi Zheng. Mol Med Rep 2015
24
12

Epigenetic Changes in Endothelial Progenitors as a Possible Cellular Basis for Glycemic Memory in Diabetic Vascular Complications.
Poojitha Rajasekar, Christina L O'Neill, Lydia Eeles, Alan W Stitt, Reinhold J Medina. J Diabetes Res 2015
45
12

Cardiovascular risk factors and metabolic control in type 2 diabetic subjects attending outpatient clinics in Italy: the SFIDA (survey of risk factors in Italian diabetic subjects by AMD) study.
Marco Comaschi, Carlo Coscelli, Domenico Cucinotta, Pierluigi Malini, Enzo Manzato, Antonio Nicolucci. Nutr Metab Cardiovasc Dis 2005
35
12

Genome-wide DNA methylation analysis of human pancreatic islets from type 2 diabetic and non-diabetic donors identifies candidate genes that influence insulin secretion.
Tasnim Dayeh, Petr Volkov, Sofia Salö, Elin Hall, Emma Nilsson, Anders H Olsson, Clare L Kirkpatrick, Claes B Wollheim, Lena Eliasson, Tina Rönn,[...]. PLoS Genet 2014
299
12

Effects of intensive glucose lowering in type 2 diabetes.
Hertzel C Gerstein, Michael E Miller, Robert P Byington, David C Goff, J Thomas Bigger, John B Buse, William C Cushman, Saul Genuth, Faramarz Ismail-Beigi, Richard H Grimm,[...]. N Engl J Med 2008
12


Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC.
John M Lachin, Neil H White, Dean P Hainsworth, Wanjie Sun, Patricia A Cleary, David M Nathan. Diabetes 2015
182
12



Hypothesis: the 'metabolic memory', the new challenge of diabetes.
M A Ihnat, J E Thorpe, A Ceriello. Diabet Med 2007
118
12

Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection.
Daisuke Katagiri, Yoshifumi Hamasaki, Kent Doi, Koji Okamoto, Kousuke Negishi, Masaomi Nangaku, Eisei Noiri. J Am Soc Nephrol 2013
48
12

Prolonged metformin treatment leads to reduced transcription of Nrf2 and neurotrophic factors without cognitive impairment in older C57BL/6J mice.
Joanne S Allard, Evelyn J Perez, Koji Fukui, Priscilla Carpenter, Donald K Ingram, Rafael de Cabo. Behav Brain Res 2016
55
12

10-year follow-up of intensive glucose control in type 2 diabetes.
Rury R Holman, Sanjoy K Paul, M Angelyn Bethel, David R Matthews, H Andrew W Neil. N Engl J Med 2008
12


Metabolic regulation of neuronal plasticity by the energy sensor AMPK.
Wyatt B Potter, Kenneth J O'Riordan, David Barnett, Susan M K Osting, Matthew Wagoner, Corinna Burger, Avtar Roopra. PLoS One 2010
129
12

Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g).
Khalid Alrasadi, Zuhier Awan, Khalid Alwaili, Isabelle Ruel, Anouar Hafiane, Larbi Krimbou, Jacques Genest. Am J Cardiol 2008
18
12

Sex Differences in the Cardiovascular Consequences of Diabetes Mellitus: A Scientific Statement From the American Heart Association.
Judith G Regensteiner, Sherita Golden, Amy G Huebschmann, Elizabeth Barrett-Connor, Alice Y Chang, Deborah Chyun, Caroline S Fox, Catherine Kim, Nehal Mehta, Jane F Reckelhoff,[...]. Circulation 2015
169
12


miR-23b-3p induces the cellular metabolic memory of high glucose in diabetic retinopathy through a SIRT1-dependent signalling pathway.
Shuzhi Zhao, Tao Li, Jun Li, Qianyi Lu, Changjing Han, Na Wang, Qinghua Qiu, Hui Cao, Xun Xu, Haibing Chen,[...]. Diabetologia 2016
65
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.